Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer
Fernando J. de Miguel, Claudia Gentile, William W. Feng, et al.
Cancer Cell (2023) Vol. 41, Iss. 8, pp. 1516-1534.e9
Open Access | Times Cited: 53

Showing 1-25 of 53 citing articles:

Targeting ROS in cancer: rationale and strategies
Christophe Glorieux, Shihua Liu, Dunyaporn Trachootham, et al.
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 8, pp. 583-606
Closed Access | Times Cited: 120
Therapeutic advances of targeting receptor tyrosine kinases in cancer
Ciprian Tomuleasa, Adrian Bogdan Țigu, Raluca Munteanu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 24
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor
Warren Fiskus, Jessica Piel, Michael Collins, et al.
Blood (2024) Vol. 143, Iss. 20, pp. 2059-2072
Open Access | Times Cited: 18
The Epigenetic Hallmarks of Cancer
Manel Esteller, Mark A. Dawson, Cigall Kadoch, et al.
Cancer Discovery (2024) Vol. 14, Iss. 10, pp. 1783-1809
Closed Access | Times Cited: 17
The Role of SWI/SNF Complex in Bladder Cancer
Zhenlain Lei, Yanfeng Han, John B. Liao, et al.
Journal of Cellular and Molecular Medicine (2025) Vol. 29, Iss. 1
Open Access | Times Cited: 2
Discovery of FHD-286, a First-in-Class, Orally Bioavailable, Allosteric Dual Inhibitor of the Brahma Homologue (BRM) and Brahma-Related Gene 1 (BRG1) ATPase Activity for the Treatment of SWItch/Sucrose Non-Fermentable (SWI/SNF) Dependent Cancers
Rishi G. Vaswani, David S. Huang, Neville J. Anthony, et al.
Journal of Medicinal Chemistry (2025)
Closed Access | Times Cited: 2
Transcription factor ZNF263 enhances EGFR-targeted therapeutic response and reduces residual disease in lung adenocarcinoma
Jiaqi Liang, Guoshu Bi, Qihai Sui, et al.
Cell Reports (2024) Vol. 43, Iss. 2, pp. 113771-113771
Open Access | Times Cited: 13
Chromatin remodellers as therapeutic targets
Hayden A. Malone, Charles W.M. Roberts
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 9, pp. 661-681
Closed Access | Times Cited: 11
A cohort-based multi-omics identifies nuclear translocation of eIF5B /PD-L1/CD44 complex as the target to overcome Osimertinib resistance of ARID1A-deficient lung adenocarcinoma
Dantong Sun, Helei Hou, Feiyue Feng, et al.
Experimental Hematology and Oncology (2025) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Fracture-healing effects of Rhizoma Musae ethanolic extract: An integrated study using UHPLC-Q-Exactive-MS/MS, network pharmacology, and molecular docking
Jian Zhang, Wanyan Shen, Fanzhi Liu, et al.
PLoS ONE (2025) Vol. 20, Iss. 1, pp. e0313743-e0313743
Open Access | Times Cited: 1
SMARCA4 controls state plasticity in small cell lung cancer through regulation of neuroendocrine transcription factors and REST splicing
Esther Redín, Harsha Sridhar, Yingqian A. Zhan, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 7
Thermal ablation included in multimodality treatment predicts enhanced survival in advanced non-small cell lung cancer: a propensity score-matched outcome study
Stella Chin‐Shaw Tsai, Yimin Chen, Yueh-Han Ku, et al.
International Journal of Hyperthermia (2025) Vol. 42, Iss. 1
Open Access
It’s all downstream from here: RTK/Raf/MEK/ERK pathway resistance mechanisms in glioblastoma
Rebeca Yakubov, Ramneet Kaloti, Phooja Persaud, et al.
Journal of Neuro-Oncology (2025)
Open Access
Two Cysteines in Raf Kinase Inhibitor Protein Make Differential Contributions to Structural Dynamics In Vitro
Hyun Sang Cho, Mohammad Faysal Al Mazid, Eun‐Young Lee, et al.
Molecules (2025) Vol. 30, Iss. 2, pp. 384-384
Open Access
Protocol to identify small-molecule inhibitors against cancer drug resistance
Juan Wei, She-Yu Zhang, Xueyuan Zhou, et al.
STAR Protocols (2025) Vol. 6, Iss. 1, pp. 103605-103605
Closed Access
Excessive MYC Orchestrates Macrophages induced Chromatin Remodeling to Sustain Micropapillary‐Patterned Malignancy in Lung Adenocarcinoma
Xuming Song, Zehao Pan, Yi Zhang, et al.
Advanced Science (2025)
Open Access
Safety, pharmacokinetics and efficacy of HA121-28 in patients with advanced solid tumors and RET fusion-positive non-small-cell lung cancer: a multicenter, open-label, single-arm phase 1/2 trial
Dan‐Yun Ruan, Wenwen Huang, Yongsheng Li, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access
Epigenetic Modification and Tumor Immunity: Unraveling the Interplay with the Tumor Microenvironment and its Therapeutic Vulnerability and Implications
Huaijin Zheng, Yuze Hua, Sen Yang, et al.
Cancer Letters (2025) Vol. 616, pp. 217587-217587
Closed Access
Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations
Warren Fiskus, Christopher P. Mill, Jessica Piel, et al.
Blood Cancer Journal (2025) Vol. 15, Iss. 1
Open Access
The clinical-grade CBP/ p300 inhibitor CCS1477 represses the global NRF2-dependent cytoprotective transcription program and re-sensitizes cancer cells to chemotherapeutic drugs
Ke Wang, Liam Baird, Masayuki Yamamoto
Free Radical Biology and Medicine (2025)
Closed Access
Tyr1497 in the BRG1 Bromodomain of the SWI/SNF Complex is Critical for the Binding and Function of a Selective BRG1 Inhibitor
Yinan Wang, Chuanhe Yang, Gustavo A. Miranda‐Carboni, et al.
Journal of Cellular and Molecular Medicine (2025) Vol. 29, Iss. 6
Open Access
Multi-omic profiling in breast cancer: utility for advancing diagnostics and clinical care
Emna El Gazzah, Scott Parker, Mariaelena Pierobon
Expert Review of Molecular Diagnostics (2025)
Closed Access
METTL16-dependent miR-146b-5p m6A modification remodeling sensitize NSCLC to osimertinib via activating PI3K/AKT signaling
Hongyang Sang, Jinlong Liu, Xifang Chen, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Targeting KRAS-G12C in Lung Cancer: The Emerging Role of PROTACs in Overcoming Resistance
Kumarappan Chidambaram, Arcot Rekha, Ahsas Goyal, et al.
Pathology - Research and Practice (2025), pp. 155954-155954
Closed Access
Metastatic INI-1−deficient undifferentiated lung cancer with EGFR 19del mutation identified in pleural effusion: a case report and review of the literature
Zhen Guo, Tianyuan Li, Xiu-fang Duan
Frontiers in Oncology (2025) Vol. 15
Open Access
Page 1 - Next Page

Scroll to top